Merus

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Merus touts cancer drug's strong profile with new data drop

Along with the company's new data drop, Merus also secured a partner for its first-in-class NRG1 fusion-positive cancer candidate.
Zoey Becker Dec 2, 2024 11:59am
delay

FDA delays decision on Merus' first-in-class cancer drug

Nov 5, 2024 9:14am
target reach ladder climb meet win beat competition

Merus cancer bispecific lives up to investors' expectations

May 24, 2024 8:53am
Graphic of two hands shaking under a red and purple light

Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers

Mar 6, 2024 10:02am
down bankruptcy end arrow

Merus shares dip as lung cancer data reveal 3 patient deaths

Dec 4, 2023 1:04pm
pushing rock up hill battle double hard difficult

Merus' NRG1+ drug responses edge up in tough pancreatic cancer

Oct 23, 2023 7:30am